By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical
When it comes to conducting clinical trials, most emerging companies choose to access external resources through partnering with CROs. That is what makes Martin Lehr, CEO of Context Therapeutics different. He prefers to bypass CROs and take part in Investigator-Sponsored Trials (ISTs).